Purpose Surgical site infection (SSI) is a major concern in colorectal surgery (CRS). It accounts for 60 % of all postoperative complications and has an incidence of between 10 and 30 %. The gentamicin-collagen sponge (GCS) was developed to help avoid SSI. The aim of this study was the evaluation of the efficacy of a GCS in preventing SSI after CRS. Method This study was a retrospective analysis of data collected in a prospective database. Six hundred six CRS patients were enrolled in the study and prospectively assigned to one of two groups.
Introduction
Postoperative surgical site infection (SSI) constitutes a major concern in colorectal surgery (CRS). It accounts for 60 % of all postoperative complications and has an incidence of between 10 and 30 % [1] [2] [3] . Surgical site infections increase morbidity, length of hospitalization, and cost and may necessitate invasive endoscopic or surgical procedures. It has been suggested that some nonpharmacological treatments can reduce the incidence of SSI: skin preparation, mechanical bowel preparation, wound protectors, hyperoxia, and warming [4] [5] [6] . The gentamicin-collagen sponge (GCS) was developed to avoid wound infections by providing high local gentamicin concentrations but not the high systemic concentrations associated with nephrotoxicity [4] . The sponge's collagen matrix is biodegradable and can be inserted as an inlay or in the organ space. The GCS was first approved in Germany in 1985 and is currently used in over 60 countries. The GCS's efficacy and safety in digestive surgery have been assessed in several controlled studies. A literature review [7] , four randomized, controlled trials (RCTs) [8] [9] [10] [11] , and a prospective, nonrandomized study [12] all concluded that use of a GCS reduced the incidence of SSI. In view of these results, our university medical center started to use GCSs in early 2009. More recently, an RCT [5] with a large patient population (n0 602) contradicted the literature results by evidencing a higher SSI rate in a group of patients having received a GCS during digestive surgery. Given these contrasting findings and with a view to taking a definitive decision on GCS use in our institution, we decided to contribute additional, center-specific data concerning the efficacy of the GCS by comparing a historical non-GCS cohort of patients with a prospective GCS cohort on the basis of the same prospective database dedicated to SSI surveillance.
Patients and methods

Trial design
Between January 2007 and July 2011, 606 patients underwent colorectal surgery in the Department of Digestive Surgery at Amiens University Medical Center. All patients were operated on by one of our two colorectal surgeons (OB, AD). In order to assess the value of GCS in preventing post-CRS SSI, we assigned the patients into one of two groups by time period. From January 2007 to December 2008, surgical procedures were performed without a GCS (forming the non-GCS group). From January 2009 to July 2011, a GCS was systematically used (forming the GCS group). Data on the historical control group (non-GCS group) and the treatment group (GCS group) were prospectively collected in an electronic database. There were no significant changes to the surgical and care teams during the overall study period (see section "Perioperative data collection").
Ethics
The GCS has been approved in France since 2001, and we have used it routinely since January 2009. All patients were informed of the use of GCS before surgical procedure. The study's objectives and procedures were approved by our institution's independent investigational review board as a noninterventional research (CEERNI 42).
Inclusion and exclusion criteria
Included patients were aged 18 or over and had undergone elective or emergency colorectal laparoscopy or laparotomy.
We excluded those of ages under 18 and patients with aminoside allergy or kidney failure.
Patients
Patients were operated on for colorectal cancer or benign lesions (diverticulitis, inflammatory bowel disease, ischemia, and miscellaneous conditions). Colon resection was always performed. Anastomosis or Hartman procedure was performed depending on the type of surgery, pathology, local conditions (i.e. peritonitis), or general conditions. Whenever possible, we performed an anastomosis. Sometimes, in cases of peritonitis, preoperative fecal incontinence, or cardiovascular collapsus, we preferred to achieve a stoma without anastomosis. When anastomosis was performed, a diverting stoma was created in some (but not all) cases.
Definitions
Postoperative surgical site infections
We recorded the presence or absence of SSIs occurring within 30 days of the surgical procedure. SSIs are usually classified into three categories [13] (Table 1) . Postoperative morbidity and mortality were described according to Clavien's classification [14] ( Table 1) . The Altemeier classification characterizes surgical wounds [15] (Table 1 ). The risk of infection was assessed with the use of the National Nosocomial Infection Surveillance System (NNIS), a composite index that aggregates the Altemeier classification, the American Society of Anesthesiology score (ASA), and the operating time [16] .
Surgical procedure
Preoperative work-up was performed according to the current guidelines [17, 18] . All patients were admitted on the day before surgery. Colon enema was not performed for colon resection [17] . For rectal resection, the bowel was prepared by administration of oral laxatives and retrograde enemas [18] . Senna solution (X-Prep® from Laboratoires Sarget, Mérignac, France) was provided 24 h before the operation. Perioperative prophylactic antibiotics (500 mg of metronidazole and 1 g of ceftriaxone in 125 mg of saline solution) were infused intravenously for 15 min following the induction of anesthesia. Prophylactic antibiotics were again infused 30 min after skin incision and then every 2 h during the surgical procedure (in accordance with French national guidelines [19] ).
Sponge insertion
Collatamp® sponges (10 by 10 cm, from Eusapharma, Limonest, France) contained 280 mg of collagen and 200 mg of gentamicin sulfate. The implantation of one gentamicin-collagen sponge (corresponding to a gentamicin dose of 130 mg) results in local-tissue gentamicin concentrations of 170 μg per milliliter. Systemic concentrations of gentamicin remained below 2 μg per milliliter 24 h after implantation [20] . Sponges were placed directly onto the tissue without prior wetting. For procedures with anastomosis and under laparotomy or laparoscopy, a circular perianastomotic sponge was inserted after anastomosis creation. For procedures in the absence of anastomosis, Collatamp® sponges were inserted close to a suture (e.g., at the rectal stump). Collatamp® sponges were placed at every time (laparotomy or laparoscopy) around the colorectal anastomosis or around the rectal stump in case of Hartmann procedure. For laparotomy procedures, a sponge was inserted into the abdominal wall.
Perioperative data collection: SSIs, Clavien grading, and follow-up Since January 2007, we have fully documented each operation in a prospective database (DxCare® from Medasys, Gif-sur-Yvette, France) by recording preoperative variables (height, weight, BMI, diabetes antecedents, age, gender, ASA score, etiology (cancer, diverticulitis, inflammatory bowel disease or other), emergency, or elective surgery), preoperative variables (organ group, operating time, Altemeier classification, type of surgery, presence or absence of anastomosis, and presence or absence of a protective stoma), underlying disease (cancer, diverticulitis, inflammatory bowel disease), and postoperative variables (medical or surgical complications, SSI occurrence, length of postoperative hospitalization (LPH), NNIS grade, and Clavien grade) [21] . A total of 606 patients who underwent colorectal surgery were enrolled in this study. We assigned the patients into two groups by period of time. From January 2007 to December 2008, all procedures were performed without the use of GCS (non-GCS group). From January 2009 to July 2011, all procedures included a GCS (GCS group). Morbidity was documented at the time of occurrence (Clavien I-V) or, in the absence of complications, at discharge (Clavien 0). The SSI data were completed at postoperative day 30. In the event of SSI occurrence before postoperative day 30, the data were completed at the time of occurrence. Standard preoperative demographic and intraoperative characteristics were also recorded. At the time of study, full information on 4,990 patients was available. Data were extracted as a Excel® file (Microsoft Corporation, Redmond, WA, USA) by using Business Objects® software (version 12.1.0.882) (SAP France S.A Capital 8-32 rue de Monceau 75008 Paris).
Outcome measures
The primary endpoint was the presence or absence of SSI at postoperative day 30. Secondary endpoints were the LPH (in days) and the proportion of patients with severe postoperative outcomes (surgical, endoscopic, or radiological reintervention for SSI or Clavien III-V postoperative day 30 morbidity and mortality). Data monitoring committee
The occurrence and nature of Clavien-graded surgical complications was systematically reviewed and assessed by the study's two lead investigators (OB, JMR). Case report forms were checked for validity. In the event of aberrant findings or mismatch between the two interpretations, the reviewers met and reached a consensus.
Statistical analysis
In this prospective matched-case study, each patient in the GCS group was matched for age, gender, surgery duration, Altemeier classification, ASA score, and circumstances with two patients of the control historical non-GCS group (ratio 1:2). Matching was organized following the optimal method [22] , discarding control units outside the convex hull of the treated units [23] . The primary analysis was based on an intent-to-treat principle, in which all the patients sequentially admitted were included into the analysis, without any possible exclusion. We used a mixed model featuring a logistic regression in using blocks as random factor, matching variables as covariates, other available covariates (BMI, diabetes antecedents, use of anastomosis, and underlying disease), and treatment as fixed factor. The proportion of patient experiencing SSI was compared between groups within each NNIS category and age category (MantelHaenszel test). Time to discharge was compared between the two groups by a linear model using baseline variables. Finally, the proportion of patients with severe outcome (Clavien IIIb-V) was compared in adjusting for age (Mantel-Haenszel test). Under these assumptions, and based on a matching ratio 1:2, a sample size of at least 202 patients treated with GCS was needed to detect a SSI reduction of at least 10 % with a power of 90 %, at two-sided significance level of 0.95. No formal interim analysis was planned. An independent data and safety monitoring committee monitored the trial. All statistical analyses were performed with 
Results
Patient description and intergroup comparisons
Once 202 patients were available in the GCS group (as planned by the sample size calculation), they were matched with 404 untreated patients (non-GCS group). No patient was lost to follow-up. The sample was constituted by 42 % of women and a mean age of 63 years (range 68-79) ( Table 1 ). The two groups matched well on all the variables, for matching variables as well as for all the other baseline characteristics (diabetes, preoperative conditions, underlying disease, BMI, emergency of elective conditions, and underlying disease) ( Table 2 ).
Incidence of surgical site infection
The incidences of SSI were 29.7 % in the non-GCS group and 20.8 % in the GCS group, (odds ratio (OR)00.514, 95 % CI 0.306-0.865, p00.013). The comparison of SSI proportion between the two groups within each NNIS category (Table 3) provides evidence of a constant relative efficacy of GCS compared with control across the four categories of severity (Mantel-Hanszel, p00.019). By using a stepwise logistic regression, the predictors of SSI were found to be ASA grade (p<0.001), operating time (logtransformed value, p<0.001), gender (p00.021), and GCS use (p<0.001). After adjusting on these previous variables, all the other variables (anastomosis, BMI, diabetes duration, emergency or elective conditions of surgery, underlying disease differentiating cancer, diverticulitis, and inflammatory bowel) were not found significantly determinant of SSI. By adjusting on these variables, a mean reduction in postoperative hospitalization of 8.3 days was found in the GCS group. The proportions of Clavien IIIB-V were 16.6 and 8.9 % for the non-GCS and GCS groups, respectively (p00.041).
Secondary endpoints
We compared the mean LPH in the two treatment groups by applying a stepwise linear regression model based on baseline covariates (Table 4 When the previous variables were considered in the model, the other tested covariates (BMI, diabetes antecedents, underlying disease, type of surgery, anastomosis) were non significant, The proportion of patients with severe outcome (Clavien Grade IIIb-V) was compared between the two treatments across age categories (Table 5 ). Proportions of 16.6 and 8.9 % were found for non-GCS and GCS group, respectively. (risk ratio, RR Control/Treated 00.58, 95 % CI 0.344-0.097, p00.041). In cases of SSI, a systematical bacteriological examination was performed. There were three bacteria in Adjusted R 2 00.1418, Altemeier Index, age, circumstances, underlying disease, anastomosis use, BMI, and diabetes antecedents were excluded by stepwise regression. Mean duration corresponds to mean estimated hospitalization duration corresponding to male patients with surgery duration of 2 h, and ASA 0 grade 1 10 % of cases (n017), two bacteria in 40 % (n064), a single one in 40 % (n064), and no bacteria in 10 % (n017). The most frequent bacteria were Escherichia coli in 50 % (n0 81), Enterobacter aerogenes in 20 % (n033), Enterobacter cloacae in 10 % (n017), and Enterococcus spp in 30 % (n0 50). Table 5 shows the number and percentage of patients with Clavien grade IIIb or IV or V in the two treatment groups stratified by age.
Discussion
The primary endpoint (SSI at postoperative day 30) was compared between the two groups in estimating the difference of SSI between both groups in stratifying between each category of NNIS. We found a significant higher incidence of SSI in the control non-GCS group than in the GCS group (29.7 vs. 20.8 %, respectively). This result is in line with that of other studies on Collatamp®, with the exception of that of Bennett-Guerrero et al. [5] . Nowachi et al. found a lower postoperative complication rate in the GCS group, relative to the control group (20.7 vs. 37.5 %) [10] . De Bruin et al. found significantly lower wound complication rate (11 vs. 29 % in the GCS and non-GCS groups, respectively) [12] . Rutten et al. found lower SSI rate in the GCS group (5.6 vs. 18.4 % in the non-GCS group) [8] . In contrast, Bennett-Guerrero et al. found a higher SSI rate in the GCS group than in the control group. Bennett-Guerrero et al. suggested that the length of follow-up (not mentioned in the other studies) could explain the difference of results between their study and the others. In our study, SSI was evaluated on postoperative day 30. Cases of later complaints by the patient were fully documented in our prospective database [12] . The apparent lack of benefit of a GCS in the report of Bennett-Guerrero et al. [5] may be explained by the inlay location of GCS in their cases (compared with inlay and abdominal cavity sites in our present work). Moreover, Bennett-Guerrero et al. [5] only included patients with elective procedures, whereas our study featured both emergency and elective CRS. Our results showed that patients in the GCS group were hospitalized for 8 days less than those in the non-GCS group (on average) and thus confirmed the positive effect of Collatamp®. This finding confirms the report by de Bruin et al. on shorter hospitalization in a GCS group (15 vs. 25 days in a non-GCS group) and the report by Rutten et al. (13.8 days in a GCS group vs. 16.3 days in a non-GCS group). The shorter stay may be due to a lower SSI rate in GCS-treated patients. In our study, we had no group of patients with collagen sponge without gentamicin, and collagen is usually not used alone around the anastomoses. Collagen is used for hemostasis in general surgery, in the treatment of the liver cross section following hepatectomy, but not for an antiseptic effect [24] . Our study had a number of limitations. It was not an RCT; a consecutive series of patients received standard care, but only the last 202 were treated with a GCS. Although this design is known to be less accurate than an RCT, it has been already used in a surgical context [25] . Moreover, the study procedures were designed to minimize sources of bias: (a) before analyzing any other results, we confirmed the absence of trend over time in the SSI rate; (b) we sequentially treated all the patients, with no exclusions or exceptions; and (c) we controlled for possible baseline discrepancies. Our tests were stratified into baseline severity categories, and so the small observed intergroup differences are less likely to have influenced our results.
Conclusion
Our study provides additional evidence of the efficacy of GCS in reducing SSI rates and shortening hospitalization after colorectal surgery. In view of the recent conflicting results, further clinical studies are required.
